AR051735A1 - Inhibidores pirrolicos de la proteina quinasa erk, sintesis e intermediarios de los mismos. - Google Patents
Inhibidores pirrolicos de la proteina quinasa erk, sintesis e intermediarios de los mismos.Info
- Publication number
- AR051735A1 AR051735A1 ARP050101987A ARP050101987A AR051735A1 AR 051735 A1 AR051735 A1 AR 051735A1 AR P050101987 A ARP050101987 A AR P050101987A AR P050101987 A ARP050101987 A AR P050101987A AR 051735 A1 AR051735 A1 AR 051735A1
- Authority
- AR
- Argentina
- Prior art keywords
- inhibitors
- pirrolic
- intermediaries
- erk
- synthesis
- Prior art date
Links
- 230000015572 biosynthetic process Effects 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 102000004169 proteins and genes Human genes 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 title 1
- 238000003786 synthesis reaction Methods 0.000 title 1
- 125000001931 aliphatic group Chemical group 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 229940045988 antineoplastic drug protein kinase inhibitors Drugs 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 239000003909 protein kinase inhibitor Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Physical Education & Sports Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Transplantation (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Virology (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Biomedical Technology (AREA)
- Communicable Diseases (AREA)
- Neurosurgery (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US57130904P | 2004-05-14 | 2004-05-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR051735A1 true AR051735A1 (es) | 2007-02-07 |
Family
ID=35106760
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP050101987A AR051735A1 (es) | 2004-05-14 | 2005-05-13 | Inhibidores pirrolicos de la proteina quinasa erk, sintesis e intermediarios de los mismos. |
| ARP160103545A AR106755A2 (es) | 2004-05-14 | 2016-11-18 | Inhibidores pirrólicos de la proteína quinasa erk, síntesis e intermediarios de los mismos |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP160103545A AR106755A2 (es) | 2004-05-14 | 2016-11-18 | Inhibidores pirrólicos de la proteína quinasa erk, síntesis e intermediarios de los mismos |
Country Status (25)
| Country | Link |
|---|---|
| US (6) | US7354939B2 (enExample) |
| EP (5) | EP3943489A1 (enExample) |
| JP (1) | JP5132305B2 (enExample) |
| CN (1) | CN1976919A (enExample) |
| AR (2) | AR051735A1 (enExample) |
| AU (1) | AU2005245885B2 (enExample) |
| BR (1) | BRPI0511111A (enExample) |
| CA (1) | CA2566461C (enExample) |
| CY (1) | CY1122336T1 (enExample) |
| DK (1) | DK3305776T3 (enExample) |
| ES (4) | ES2651439T3 (enExample) |
| HU (1) | HUE047130T2 (enExample) |
| IL (1) | IL179207A0 (enExample) |
| LT (1) | LT3305776T (enExample) |
| MX (1) | MXPA06013209A (enExample) |
| NO (1) | NO20065727L (enExample) |
| NZ (1) | NZ551582A (enExample) |
| PL (1) | PL3305776T3 (enExample) |
| PT (1) | PT3305776T (enExample) |
| RU (1) | RU2376299C2 (enExample) |
| SI (1) | SI3305776T1 (enExample) |
| TW (1) | TW200607803A (enExample) |
| UA (1) | UA84930C2 (enExample) |
| WO (1) | WO2005113541A1 (enExample) |
| ZA (1) | ZA200609975B (enExample) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2522176A1 (en) * | 2003-03-13 | 2004-09-30 | Vertex Pharmaceuticals Incorporated | Compositions useful as protein kinase inhibitors |
| WO2005100342A1 (en) * | 2004-03-26 | 2005-10-27 | Vertex Pharmaceuticals, Incorporated | Pyridine inhibitors of erk2 and uses thereof |
| US7354939B2 (en) * | 2004-05-14 | 2008-04-08 | Vertex Pharmaceuticals Incorporated | Pyrrole inhibitors of ERK protein kinase, synthesis thereof and intermediates thereto |
| US8546404B2 (en) | 2005-12-13 | 2013-10-01 | Merck Sharp & Dohme | Compounds that are ERK inhibitors |
| MX2008010635A (es) * | 2006-02-16 | 2008-10-28 | Schering Corp | Derivados de pirrolidina como inhibidores de cinasa regulada por señales extracelulares. |
| EP2155722B1 (en) * | 2007-06-05 | 2013-08-14 | Merck Sharp & Dohme Corp. | Polycyclic indazole derivatives and their use as erk inhibitors for the treatment of cancer |
| WO2009105500A1 (en) | 2008-02-21 | 2009-08-27 | Schering Corporation | Compounds that are erk inhibitors |
| CN102146074B (zh) * | 2011-01-26 | 2013-02-06 | 江苏先声药物研究有限公司 | 吡咯衍生物的制备方法及应用 |
| WO2012172093A1 (en) | 2011-06-17 | 2012-12-20 | Merz Pharma Gmbh & Co. Kgaa | Dihydroindolizine derivate as metabotropic glutamate receptor modulators |
| PL3058371T3 (pl) | 2013-10-14 | 2021-11-08 | Indiana University Research And Technology Corporation | Zastosowanie akamprozatu do modulowania aktywacji erk 1-2 w modelach zwierzęcych dla fxs i asd oraz u osób z rozpoznaniem fxs i asd |
| US20160264536A1 (en) | 2013-10-23 | 2016-09-15 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
| WO2015095833A1 (en) * | 2013-12-20 | 2015-06-25 | Biomed Valley Discoveries, Inc. | Treatment of hematologic cancers |
| MX394252B (es) * | 2013-12-20 | 2025-03-21 | Biomed Valley Discoveries Inc | Tratamiento del cancer usando combinaciones de inhibidores de erk y raf |
| WO2015095842A2 (en) * | 2013-12-20 | 2015-06-25 | Biomed Valley Discoveries, Inc. | Methods and compositions for treating non-erk mapk pathway inhibitor-resistant cancers |
| US11013743B2 (en) | 2013-12-20 | 2021-05-25 | Biomed Valley Discoveries, Inc. | Cancer treatments using combinations of CDK and ERK inhibitors |
| WO2015095835A1 (en) * | 2013-12-20 | 2015-06-25 | Biomed Valley Discoveries, Inc. | Methods of modulating radioiodine uptake for the treatment of radioiodine-refractory cancers |
| JP6727127B2 (ja) * | 2013-12-20 | 2020-07-29 | バイオメッド バレー ディスカバリーズ，インコーポレイティド | Ｐｉ３ｋ／ａｋｔシグナル経路阻害剤およびｅｒｋ阻害剤の組み合わせを使用するがん処置 |
| AU2014368925A1 (en) * | 2013-12-20 | 2016-07-21 | Biomed Valley Discoveries, Inc. | Cancer treatments using combinations of MEK type I and ERK inhibitors |
| WO2015095807A1 (en) * | 2013-12-20 | 2015-06-25 | Biomed Valley Discoveries, Inc. | Cancer treatments using combinations of egfr and erk inhibitors |
| WO2015095831A1 (en) * | 2013-12-20 | 2015-06-25 | Biomed Valley Discoveries, Inc. | Cancer treatments using combinations of mtor and erk inhibitors |
| EP3082779B1 (en) * | 2013-12-20 | 2023-06-07 | Biomed Valley Discoveries, Inc. | Cancer treatments using combinations of type 2 mek and erk inhibitors |
| EP3250562B1 (en) * | 2015-01-30 | 2024-11-27 | Biomed Valley Discoveries, Inc. | Crystalline 4-(5-chloro-2-isopropylaminopyridin-4-yl)-1h-pyrrole-2-carboxylic acid [1-(3-chlorophenyl)-2-hydroxyethyl]amide hydrochloride salt |
| EP3250291B1 (en) * | 2015-01-30 | 2020-08-26 | Biomed Valley Discoveries, Inc. | Crystalline c21h22c12n4o2 malonate |
| WO2016187028A1 (en) * | 2015-05-15 | 2016-11-24 | Celgene Avilomics Research, Inc. | Heteroaryl compounds, synthesis thereof, and intermediates thereto |
| WO2016192063A1 (en) * | 2015-06-03 | 2016-12-08 | Changzhou Jiekai Pharmatech Co. Ltd | Heterocyclic compounds as erk inhibitors |
| CN106536522B (zh) * | 2015-06-03 | 2020-08-28 | 捷思英达医药技术（上海）有限公司 | 用于治疗银屑病的杂环化合物 |
| WO2017068412A1 (en) | 2015-10-21 | 2017-04-27 | Otsuka Pharmaceutical Co., Ltd. | Benzolactam compounds as protein kinase inhibitors |
| EP3170822A1 (en) | 2015-11-18 | 2017-05-24 | AGV Discovery | Azaindole derivatives and their use as erk kinase inhibitors |
| BR112019005305A2 (pt) * | 2016-10-05 | 2019-07-02 | Zeno Royalties & Milestones Llc | compostos espirocíclicos |
| GB201706327D0 (en) | 2017-04-20 | 2017-06-07 | Otsuka Pharma Co Ltd | A pharmaceutical compound |
| US11406627B2 (en) * | 2017-10-12 | 2022-08-09 | Novartis Ag | Combinations of MDM2 inhibitors with inhibitors of ERK for treating cancers |
| WO2019180141A1 (en) | 2018-03-23 | 2019-09-26 | Bayer Aktiengesellschaft | Combinations of rogaratinib |
| US20230190725A1 (en) * | 2019-04-29 | 2023-06-22 | The Board Of Trustees Of The University Of Illinois | Mek inhibitors for corneal scarring and neovascularization |
| WO2021020841A1 (en) * | 2019-07-29 | 2021-02-04 | Standigm Inc. | Composition for preventing or treating metabolic liver disease |
| EP4212531A1 (en) | 2022-01-14 | 2023-07-19 | AGV Discovery | Azaindole derivatives and their use as erk kinase inhibitors |
| WO2023169480A1 (zh) * | 2022-03-08 | 2023-09-14 | 甘李药业股份有限公司 | 氘代化合物，及其制备方法和应用 |
| CN119212985A (zh) * | 2022-03-24 | 2024-12-27 | 生物医学谷探索股份有限公司 | Erk的吡咯抑制剂的氘代类似物、其合成及其中间体 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5304121A (en) | 1990-12-28 | 1994-04-19 | Boston Scientific Corporation | Drug delivery system making use of a hydrogel polymer coating |
| US5886026A (en) | 1993-07-19 | 1999-03-23 | Angiotech Pharmaceuticals Inc. | Anti-angiogenic compositions and methods of use |
| US5565413A (en) * | 1994-12-06 | 1996-10-15 | Zeneca Limited | Substituted pyridyl phenyl ketone herbicides |
| US5472966A (en) * | 1995-03-29 | 1995-12-05 | Bristol-Myers Squibb Company | Antidepressant heteroarylaminoalkyl derivatives of naphthyl-monazines |
| US6099562A (en) | 1996-06-13 | 2000-08-08 | Schneider (Usa) Inc. | Drug coating with topcoat |
| IL146465A0 (en) * | 1999-05-14 | 2002-07-25 | Ortho Mcneil Pharm Inc | Substituted 3-pyridyl-4-arylpyrroles and related therapeutic and prophylactic methods |
| AU5566300A (en) * | 1999-06-22 | 2001-01-09 | Takeda Chemical Industries Ltd. | Acylhydrazine derivatives, process for preparing the same and use thereof |
| MY130778A (en) * | 2001-02-09 | 2007-07-31 | Vertex Pharma | Heterocyclic inhibitiors of erk2 and uses thereof |
| EP1506189A1 (en) | 2002-04-26 | 2005-02-16 | Vertex Pharmaceuticals Incorporated | Pyrrole derivatives as inhibitors of erk2 and uses thereof |
| JP4570955B2 (ja) * | 2002-07-09 | 2010-10-27 | バーテクス ファーマスーティカルズ インコーポレイテッド | プロテインキナーゼ阻害活性を持つイミダゾール類 |
| SI2256108T1 (sl) | 2002-07-18 | 2016-05-31 | Janssen Pharmaceutica N.V. | Substituirani triazinski kinazni inhibitorji |
| GB0217780D0 (en) * | 2002-07-31 | 2002-09-11 | Glaxo Group Ltd | Compounds |
| US7304071B2 (en) * | 2002-08-14 | 2007-12-04 | Vertex Pharmaceuticals Incorporated | Protein kinase inhibitors and uses thereof |
| CA2522176A1 (en) * | 2003-03-13 | 2004-09-30 | Vertex Pharmaceuticals Incorporated | Compositions useful as protein kinase inhibitors |
| US7354939B2 (en) * | 2004-05-14 | 2008-04-08 | Vertex Pharmaceuticals Incorporated | Pyrrole inhibitors of ERK protein kinase, synthesis thereof and intermediates thereto |
-
2005
- 2005-05-13 US US11/128,870 patent/US7354939B2/en not_active Ceased
- 2005-05-13 UA UAA200613208A patent/UA84930C2/ru unknown
- 2005-05-13 MX MXPA06013209A patent/MXPA06013209A/es active IP Right Grant
- 2005-05-13 SI SI200532267T patent/SI3305776T1/sl unknown
- 2005-05-13 CN CNA200580021418XA patent/CN1976919A/zh active Pending
- 2005-05-13 BR BRPI0511111-0A patent/BRPI0511111A/pt not_active IP Right Cessation
- 2005-05-13 AR ARP050101987A patent/AR051735A1/es not_active Application Discontinuation
- 2005-05-13 ES ES14163944.3T patent/ES2651439T3/es not_active Expired - Lifetime
- 2005-05-13 WO PCT/US2005/016902 patent/WO2005113541A1/en not_active Ceased
- 2005-05-13 ZA ZA200609975A patent/ZA200609975B/en unknown
- 2005-05-13 DK DK17184079T patent/DK3305776T3/da active
- 2005-05-13 PT PT171840796T patent/PT3305776T/pt unknown
- 2005-05-13 TW TW094115644A patent/TW200607803A/zh unknown
- 2005-05-13 EP EP21190432.1A patent/EP3943489A1/en active Pending
- 2005-05-13 CA CA2566461A patent/CA2566461C/en not_active Expired - Lifetime
- 2005-05-13 JP JP2007513432A patent/JP5132305B2/ja not_active Expired - Lifetime
- 2005-05-13 RU RU2006144445/04A patent/RU2376299C2/ru active
- 2005-05-13 HU HUE17184079A patent/HUE047130T2/hu unknown
- 2005-05-13 EP EP05748073.3A patent/EP1753738B1/en not_active Expired - Lifetime
- 2005-05-13 ES ES19199330T patent/ES2897422T3/es not_active Expired - Lifetime
- 2005-05-13 EP EP19199330.2A patent/EP3608315B1/en not_active Expired - Lifetime
- 2005-05-13 PL PL17184079T patent/PL3305776T3/pl unknown
- 2005-05-13 AU AU2005245885A patent/AU2005245885B2/en not_active Expired
- 2005-05-13 EP EP14163944.3A patent/EP2799434B1/en not_active Expired - Lifetime
- 2005-05-13 LT LTEP17184079.6T patent/LT3305776T/lt unknown
- 2005-05-13 NZ NZ551582A patent/NZ551582A/en not_active IP Right Cessation
- 2005-05-13 ES ES17184079T patent/ES2751761T3/es not_active Expired - Lifetime
- 2005-05-13 EP EP17184079.6A patent/EP3305776B1/en not_active Expired - Lifetime
- 2005-05-13 ES ES05748073.3T patent/ES2513965T3/es not_active Expired - Lifetime
-
2006
- 2006-11-13 IL IL179207A patent/IL179207A0/en unknown
- 2006-12-12 NO NO20065727A patent/NO20065727L/no not_active Application Discontinuation
-
2013
- 2013-08-23 US US14/544,396 patent/USRE46097E1/en not_active Expired - Lifetime
-
2016
- 2016-06-28 US US15/195,021 patent/USRE47318E1/en not_active Expired - Lifetime
- 2016-11-18 AR ARP160103545A patent/AR106755A2/es active IP Right Grant
-
2019
- 2019-03-25 US US16/363,905 patent/USRE48266E1/en not_active Expired - Lifetime
- 2019-12-03 CY CY20191101265T patent/CY1122336T1/el unknown
-
2020
- 2020-10-15 US US17/071,566 patent/USRE49500E1/en not_active Expired - Lifetime
-
2023
- 2023-02-22 US US18/173,004 patent/US20230183276A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR051735A1 (es) | Inhibidores pirrolicos de la proteina quinasa erk, sintesis e intermediarios de los mismos. | |
| AR045595A1 (es) | Composiciones utiles como inhibidores de proteinas quinasas | |
| BRPI0509369A (pt) | azaindóis úteis como inibidores de jak e outras proteìna cinases | |
| ECSP034865A (es) | Resolución óptica de (1-benzilo-4-metilopiperidina-3-il)-metilamina y su uso para la preparación de derivados de pirrolo 2,3-pirimidina como inhibidores de proteina quinasas | |
| UA87153C2 (ru) | Энантиомерно чистые аминогетероарильные соединения как ингибиторы протеинкиназы | |
| GT200600143A (es) | Fenilacetamidas apropiadas como inhibidores de la proteina kinasa | |
| EA201070395A1 (ru) | Ингибиторы polo-подобных киназ | |
| EA200501332A1 (ru) | Производные пиримидин-4-она и их применение в качестве модуляторов киназы p38 | |
| GT200800258A (es) | Compuestos de pirrolo-pirimidina y sus usos | |
| EA200700192A1 (ru) | Производные фталазина в качестве ингибиторов parp | |
| PE20070218A1 (es) | COMPUESTOS DE CICLOALQUILO AMINO-HIDANTOINA Y USO DE ESTOS PARA LA MODULACION DE ß-SECRETASA | |
| UY28946A1 (es) | Compuestos de aril-y heteroaril-alquilanina que contienen pirazol, composiciones farmacéuticas que contienen los compuestos y nuevos productos químicos intermedios | |
| ECSP066541A (es) | Nuevos derivados de piridazin-3(2h)-ona | |
| ECSP105253A (es) | Derivados de 5-feniltiazol y uso como inhibidores de pi3 cinasa | |
| CL2012000059A1 (es) | Compuestos derivados de pirazolo[1,5-a]pirimidina; proceso de preparacion; composicion farmaceutica que los comprende; y su uso como inhbidores de trk-quinasa para el tratamiento de enfermedades o trastornos tales como dolor, cancer, inflamacion; entre otras. | |
| PA8609201A1 (es) | Piridinonas sustituidas | |
| UY28859A1 (es) | Antagonistas de cgrp seleccionados, procedimiento para su preparación así como su uso como medicamento | |
| DOP2006000084A (es) | Compuestos sulfoximino-macrociclicos y sus sales, composiciones farmaceuticas que comprenden dichos compuestos, metodos de preparacion y usos de los mismos | |
| SE0403171D0 (sv) | New compounds | |
| PA8575601A1 (es) | Procedimiento para su preparacion, medicamentos que comprenden estos compuestos y su uso | |
| EA200700901A1 (ru) | Производные 2-амидо-4-фенилтиазола, их получение и применение в терапии | |
| CR9407A (es) | Tetrahidropiridoazepin-8-onas y compuestos relacionados para el tratamiento de la esquizofrenia | |
| AR051795A1 (es) | Derivados de hidantoina inhibidores de metaloproteinasas | |
| UY29818A1 (es) | Nuevos compuestos de azetidina, composiciones farmaceuticas que los contienen, procesos de preparacion y sus usos terapeuticos | |
| AR051796A1 (es) | Derivados de hidantoina como inhibidores de metaloproteinasas |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |